Bioscience

Oncolin Appoints Member of National Cancer Institute Advisory Board to Its Scientific Advisory Board

June 30, 2008

By Flinn Foundation

[Source: HOUSTON, BUSINESS WIRE] – Oncolin Therapeutics, Inc., is very pleased to announce that Dr. Daniel Von Hoff has joined the company’s Scientific Advisory Board (SAB). Dr. Von Hoff is generally considered to be one of the world’s leading experts in oncology drug development and is an advisor in some capacity to a large number of oncology companies.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in June 2004.

Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX’ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). He is founder and the Editor Emeritus of Investigational New Drugs ‘ The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics.

Daniel D. Von Hoff, M.D., is currently Physician in Chief, Senior Investigator and Director of Translational Research at the Translational Genomics Research Institute’s (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and Chief Scientific Officer, Scottsdale Clinical Research Institute. He has done work on the development of many anticancer agents, including paclitaxel, docetaxel, gemcitabine, camptosar and hab-paclitaxel.

‘Oncolin Therapeutics is very excited to have someone with Dr Von Hoff’s stature and experience as a member of our SAB. His oncology development experience will be a major addition to our advisory board,’ said Dr. Donald Picker, COO of Oncolin.